An investigation for investors in Immunomedics, Inc. (NASDAQ:IMMU) shares over potential securities laws violations by Immunomedics was announced and NASDAQ:IMMU stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 08/11/2015 --An investigation for investors in NASDAQ:IMMU shares was announced concerning potential securities laws violations by Immunomedics and certain of its directors and officers in connection certain financial statements.

Investors who purchased shares of Immunomedics, Inc. (NASDAQ:IMMU), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Immunomedics, Inc. (NASDAQ:IMMU) concerning whether a series of statements by Immunomedics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On July 28, 2015, Immunomedics, Inc. (NASDAQ:IMMU) reported that licensing partner, UCB, SA, announced that the two EMBODY™ Phase 3 clinical trials for epratuzumab in Systemic Lupus Erythematosus (SLE) did not meet the primary clinical efficacy endpoints in either dose in both studies. Shares of Immunomedics, Inc. (NASDAQ:IMMU) declined from $4.32 per share on July 14, 2015, to as low as $1.83 per share on July 28, 2015.

On August 7, 2015, NASDAQ:IMMU shares closed at $1.82 per share.

Those who purchased shares of Immunomedics, Inc. (NASDAQ:IMMU) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com